


PRODUCT INFORMATION



CCR4 Antagonist (hydrochloride)

Item No. 21885

CAS Registry No.: 1784252-84-1
Formal Name: 2-[1,4'-bipiperidin]-1'-yl-N-cycloheptyl-6,7-dimethoxy-4-quinazolinamine, dihydrochloride
MF: C₂₇H₄₁N₅O₂ • 2HCl
FW: 540.6
Purity: ≥98%
UV/Vis.: λ_{max}: 214, 248 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CCR4 antagonist (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the CCR4 antagonist (hydrochloride) in the solvent of choice, which should be purged with an inert gas. CCR4 antagonist (hydrochloride) is soluble in organic solvents such as ethanol and DMSO. The solubility of CCR4 antagonist (hydrochloride) in these solvents is approximately 5 and 25 mg/ml, respectively.

Description

Chemokine (C-C motif) receptor 4 (CCR4) antagonist is an antagonist of CCR4.¹ It inhibits activation of CCR4 by chemokine (C-C motif) ligand 22 (CCL22) in a [³⁵S]GTPγS assay and also inhibits chemotaxis in human and mouse CCR4-expressing B300-19 cells (IC₅₀s = 18, 140, and 39 nM, respectively). CCR4 antagonist inhibits microglial activation in the cortex in a mouse model of hepatic encephalopathy induced by the neurotoxin azoxymethane when administered at a dose of 1 mg/kg per day.² It reduces azoxymethane-induced increases in *Il6* and *Il1b* expression in mouse cortex. CCR4 antagonist reduces mechanical and thermal sensitivity in a mouse model of type I diabetes induced by streptozotocin (Item No. 13104) when administered intrathecally at doses ranging from 10 to 30 μg/animal.³

Reference

1. Yokoyama, K., Ishikawa, N., Igarashi, S., *et al.* Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines. *Bioorg. Med. Chem.* **16**(14), 7021-7032 (2008).
2. McMillin, M., Frampton, G., Thompson, M., *et al.* Neuronal CCL2 is upregulated during hepatic encephalopathy and contributes to microglia activation and neurological decline. *J. Neuroinflammation* **11**, 121 (2014).
3. Bogacka, J., Ciapała, K., Pawlik, K., *et al.* Blockade of CCR4 diminishes hypersensitivity and enhances opioid analgesia - Evidence from a mouse model of diabetic neuropathy. *Neuroscience* **441**, 77-92 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/24/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM